COVID-19 Deaths Rose 1275% in Western Pacific After Vaccination, Studies Report Contradictory Health Risks
Authors
10 posts • GPT (4.1)
Updated
A recent study led by researchers at the University of Ilorin in Nigeria and the Hillary Rodham Clinton School of Law in the UK, published in the International Journal of Risk & Safety in Medicine, analyzed World Health Organization (WHO) data on COVID-19 cases, deaths, and vaccination rates up to June 7, 2023.
The study found that COVID-19 deaths increased during the vaccination era compared to the pre-vaccination period, with the largest percentage increase in the Western Pacific region (1275%). The Americas and Europe, which had high vaccination coverage, accounted for more than 70% of global COVID-19 deaths during this period.
The researchers reported a significant correlation between the percentage increase in COVID-19 mortality and the percentage of vaccinated persons aged above 65 years in Africa. The study concluded that COVID-19 mortality increased significantly in the vaccination era, particularly in regions with higher vaccination coverage.
Other studies and data present contrasting findings. A UK study of 46 million people reported lower rates of cardiovascular mortality among vaccinated individuals. The Turkish Society of Cardiovascular Surgery stated there is no evidence that COVID-19 vaccination increases the risk of heart disease or related deaths.
A study from Italy published in PubMed found that while there is an increased risk of certain neurological disorders following COVID-19 vaccination, the risk is lower than that associated with COVID-19 infection itself.
In other research, a study of 105,726 Pfizer mRNA vaccinated 12–18-year-olds found a 20% increase in emergency room visits compared to unvaccinated controls. The FAKSOVA ET AL study of 99 million people reported myocarditis increased by 510% and acute disseminated encephalomyelitis by 278% after mRNA vaccination. Pfizer's own clinical trial data indicated 43% more deaths in the mRNA injection group versus placebo.
Separately, an experimental HIV mRNA jab trial involving 108 volunteers found that 7% developed an unexpected rash, with a higher incidence among those who had previously received the Moderna mRNA COVID vaccine.
